In addition to angiotensin-converting enzyme inhibitors and angiotensin receptor
blockers, direct renin inhibitors emerged as an attractive option to inhibit the renin-angiotensin system and thus to prevent cardiovascular damage. Based on the publication of the most recent available results of ALTITUDE and ASTRONAUT, we review the data with respect to the direct renin inhibitor aliskiren given as an antihypertensive drug, in monotherapy selleck chemicals and combination therapy, and the most recent publication analysing the effects of aliskiren on end-organ protection.”
“Ru/FeCoB/Ru/CoPtCr-SiO2 films were fabricated as perpendicular magnetic recording media with crystalline soft magnetic underlayer (SUL). Ru/FeCoB layers possessed high in-plane anisotropy field H-k of 400 Oe and a bcc-FeCo (110) orientation. Crystalline orientation of the FeCoB in the SUL affected on a crystallite growth of a Ru intermediate layer deposited on it and on crystallite orientation of the CoPtCr-SiO2 film deposited on the Ru intermediate layer. Ru/CoPtCr-SiO2 films without Ru/FeCoB SULs exhibited a random orientation of Ru crystallites and the in-plane CA4P concentration magnetic anisotropy. On the other hand, Ru/CoPtCr-SiO2 films deposited on the Ru/FeCoB SULs exhibited (001) preferential orientations of the CoPtCr as well as the Ru intermediate layer and possessed perpendicular
magnetic anisotropy. It was confirmed that the improvement of a bcc-FeCo (110) orientation in the SUL was effective to the improvement of a hcp-Ru (001) orientation. At the media for an intermediate layer thickness of 5 nm, the similar magnetic properties as that of 30 nm were obtained. It indicated that the BVD-523 nmr application of a crystalline SUL promoted the reduction in
the intermediate layer thickness. (c) 2009 American Institute of Physics. [DOI: 10.1063/1.3072830]“
“The objective of this study was to evaluate patients’ satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 +/- 1.